These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30347109)

  • 21. Pain Quality Assessment Scale for Epidermolysis Bullosa.
    Schräder NHB; Yuen WY; Jonkman MF
    Acta Derm Venereol; 2018 Mar; 98(3):346-349. PubMed ID: 29057428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabis and cannabinoids.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):97-8. PubMed ID: 27466748
    [No Abstract]   [Full Text] [Related]  

  • 24. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
    Loh CC; Kim J; Su JC; Daniel BS; Venugopal SS; Rhodes LM; Intong LR; Law MG; Murrell DF
    J Am Acad Dermatol; 2014 Jan; 70(1):89-97.e1-13. PubMed ID: 24355263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabidiol modulation of antinociceptive tolerance to Δ
    Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
    Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to drop the stigma: cannabinoids are drugs that may alleviate pain in people with epidermolysis bullosa.
    Martinez AE
    Br J Dermatol; 2019 Apr; 180(4):711-712. PubMed ID: 30933348
    [No Abstract]   [Full Text] [Related]  

  • 27. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
    Wade DT; Robson P; House H; Makela P; Aram J
    Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.
    Brunt TM; van Genugten M; Höner-Snoeken K; van de Velde MJ; Niesink RJ
    J Clin Psychopharmacol; 2014 Jun; 34(3):344-9. PubMed ID: 24747979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
    Notcutt W; Price M; Miller R; Newport S; Phillips C; Simmons S; Sansom C
    Anaesthesia; 2004 May; 59(5):440-52. PubMed ID: 15096238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa.
    Gewert S; Davidovic M; Has C; Kiritsi D
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1139-1144. PubMed ID: 38679781
    [No Abstract]   [Full Text] [Related]  

  • 34. Willingness to pay for a treatment for pain in multiple sclerosis.
    Iskedjian M; Desjardins O; Piwko C; Bereza B; Jaszewski B; Einarson TR
    Pharmacoeconomics; 2009; 27(2):149-58. PubMed ID: 19254047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.
    Cooper ZD; Bedi G; Ramesh D; Balter R; Comer SD; Haney M
    Neuropsychopharmacology; 2018 Sep; 43(10):2046-2055. PubMed ID: 29463913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain].
    Clermont-Gnamien S; Atlani S; Attal N; Le Mercier F; Guirimand F; Brasseur L
    Presse Med; 2002 Nov; 31(39 Pt 1):1840-5. PubMed ID: 12496714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burden of itch in epidermolysis bullosa.
    Snauwaert JJ; Yuen WY; Jonkman MF; Moons P; Naulaers G; Morren MA
    Br J Dermatol; 2014 Jul; 171(1):73-8. PubMed ID: 24506095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
    Narang S; Gibson D; Wasan AD; Ross EL; Michna E; Nedeljkovic SS; Jamison RN
    J Pain; 2008 Mar; 9(3):254-64. PubMed ID: 18088560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of saltwater baths in the treatment of epidermolysis bullosa.
    Petersen BW; Arbuckle HA; Berman S
    Pediatr Dermatol; 2015; 32(1):60-3. PubMed ID: 25644039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
    Oreja-Guevara C
    Rev Neurol; 2012 Oct; 55(7):421-30. PubMed ID: 23011861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.